Safety of varenicline in patients with cardiovascular disease

Journal of Pharmacy Practice

Volumn 27, Issue 1, 2014, Pages 65-70

  Haber, Stacy L ^a   Boomershine, Virginia ^a   Raney, Erin ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

cardiovascular disease; safety; smoking cessation; varenicline

Indexed keywords

AMFEBUTAMONE; PLACEBO; VARENICLINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG COST; DRUG SAFETY; HEART PALPITATION; HUMAN; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING CESSATION; TACHYCARDIA; THORAX PAIN; TOBACCO DEPENDENCE; TREATMENT DURATION;

CARDIOVASCULAR DISEASE; SAFETY; SMOKING CESSATION; VARENICLINE;

BENZAZEPINES; BUPROPION; CARDIOVASCULAR DISEASES; HUMANS; NICOTINIC AGONISTS; QUINOXALINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SMOKING; SMOKING CESSATION;

EID: 84892761310     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190013504961     Document Type: Review

References (25)

1. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004. www.cdc.gov/tobacco/data-statistics/sgr/2004/complete-report/ index.htm. Accessed July 29, 2012.
2. Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged ≥18 years - United States, 2005-2010. MMWR2011;60:1207-1212. www.cdc.gov/mmwr/pdf/wk/mm6035.pdf. Accessed July 29, 2012.
3. Critchely JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003 ; 290 (1). 86-97
4. Tobacco Use and Dependence Guideline Panel. Treating tobacco use and dependence: 2008 update - clinical practice guideline. www.ahrq.gov/clinic/ tobacco/treating-tobacco-use08.pdf. Accessed July 24, 2012.
5. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract. 2006 ; 60 (5). 571-576
6. Oncken C, Gonzales D, Nides M. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006 ; 166 (15). 1571-1577
7. Johnson BA. New weapon to curb smoking. Arch Intern Med. 2006 ; 166 (15). 1547-1550
8. Wu P, Wilson K, Dimoulas P, et al. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health. 2006 ; 6: 300
9. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010 ; 121 (2). 221-229
10. Institute for Safe Medication Practices. Strong safety signal seen for new varenicline risks.www.ismp.org/docs/vareniclinestudy.asp. Accessed July 29, 2012.
11. Steinberg MB, Randall J, Greenhaus S, et al. Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline. Addict Behav. 2011 ; 36 (12). 1127-1132
12. Singh S, Loke YK, Spangler JG, et al. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011 ; 183 (12). 1359-1366
13. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ. 2012 ; 344: e2856
14. Svanström H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ. 2012 ; 345: e7176
15. US Food and Drug Administration. Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease.www.fda.gov/Drugs/DrugSafety/ucm259161.htm. Accessed May 14, 2012.
16. Harrison-Woolrych M, Maggo S, Tan M, et al. Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand. Drug Saf. 2012 ; 35 (1). 33-43
17. US Food and Drug Administration. Chantix (varenicline): updated safety review on the risk of cardiovascular adverse events.www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm331626.htm. Accessed March 7, 2013.
18. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med. 1994 ; 154 ((9 )). 989-995
19. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996 ; 335 (24). 1792-1798
20. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003 ; 24 (10). 946-955
21. Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med. 2006 ; 119 (12). 1080-1087
22. Eisenberg MJ, Grandi SM, Gervais A, et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction. J Am Coll Cardiol. 2013 ; 61 (5). 524-532
23. New York, NY: Pfizer ; 2013 :
24. Williams KE, Reeves KR, Billing CB, et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007 ; 23 (4). 793-801
25. Research Triangle Park, NC: GlaxoSmithKline ; 2012: